Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

Han Bio claims success in hair multiplication using dermal papilla cells. Treatments discussed include Minoxidil, finasteride, and RU58841.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.

The user is experimenting with GHK-Cu and AHK-Cu to stop hair loss and promote hair growth, using a serum from Etsy and injectable GHK-Cu. They supplement this with dermastamping and ketoconazole shampoo.